The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents

doi:10.1093/jnci/dju436

Comparative Study

. 2015 Feb 2;107(3):dju436.

doi: 10.1093/jnci/dju436. Print 2015 Mar.

The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents

Aimée R Kreimer¹, Mark E Sherman², Vikrant V Sahasrabuddhe², Mahboobeh Safaeian²

Affiliations

¹ Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch (ARK, MS), Division of Cancer Prevention, Breast and Gynecologic Cancer Research Group (MES, VVS), Division of Cancer Epidemiology and Genetics, Human Genetics Program (MES), and Division of Cancer Epidemiology and Genetics, Hormonal and Reproductive Epidemiology Branch (VVS), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (VVS). kreimera@mail.nih.gov.
² Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch (ARK, MS), Division of Cancer Prevention, Breast and Gynecologic Cancer Research Group (MES, VVS), Division of Cancer Epidemiology and Genetics, Human Genetics Program (MES), and Division of Cancer Epidemiology and Genetics, Hormonal and Reproductive Epidemiology Branch (VVS), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (VVS).

PMID: 25650316
PMCID: PMC4326307
DOI: 10.1093/jnci/dju436

Comparative Study

The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents

Aimée R Kreimer et al. J Natl Cancer Inst. 2015.

. 2015 Feb 2;107(3):dju436.

doi: 10.1093/jnci/dju436. Print 2015 Mar.

Authors

Aimée R Kreimer¹, Mark E Sherman², Vikrant V Sahasrabuddhe², Mahboobeh Safaeian²

Affiliations

¹ Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch (ARK, MS), Division of Cancer Prevention, Breast and Gynecologic Cancer Research Group (MES, VVS), Division of Cancer Epidemiology and Genetics, Human Genetics Program (MES), and Division of Cancer Epidemiology and Genetics, Hormonal and Reproductive Epidemiology Branch (VVS), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (VVS). kreimera@mail.nih.gov.
² Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch (ARK, MS), Division of Cancer Prevention, Breast and Gynecologic Cancer Research Group (MES, VVS), Division of Cancer Epidemiology and Genetics, Human Genetics Program (MES), and Division of Cancer Epidemiology and Genetics, Hormonal and Reproductive Epidemiology Branch (VVS), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (VVS).

PMID: 25650316
PMCID: PMC4326307
DOI: 10.1093/jnci/dju436

No abstract available

PubMed Disclaimer

Cited by

National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States.
Durham DP, Ndeffo-Mbah ML, Skrip LA, Jones FK, Bauch CT, Galvani AP. Durham DP, et al. Proc Natl Acad Sci U S A. 2016 May 3;113(18):5107-12. doi: 10.1073/pnas.1515528113. Epub 2016 Apr 18. Proc Natl Acad Sci U S A. 2016. PMID: 27091978 Free PMC article.
Opportunities and challenges for human papillomavirus vaccination in cancer.
Roden RBS, Stern PL. Roden RBS, et al. Nat Rev Cancer. 2018 Apr;18(4):240-254. doi: 10.1038/nrc.2018.13. Epub 2018 Mar 2. Nat Rev Cancer. 2018. PMID: 29497146 Free PMC article. Review.
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Arbyn M, et al. Cochrane Database Syst Rev. 2018 May 9;5(5):CD009069. doi: 10.1002/14651858.CD009069.pub3. Cochrane Database Syst Rev. 2018. PMID: 29740819 Free PMC article.
An investigation into the role of chronic Schistosoma mansoni infection on Human Papillomavirus (HPV) vaccine induced protective responses.
Gent V, Waihenya R, Kamau L, Nyakundi R, Ambala P, Kariuki T, Ochola L. Gent V, et al. PLoS Negl Trop Dis. 2019 Aug 26;13(8):e0007704. doi: 10.1371/journal.pntd.0007704. eCollection 2019 Aug. PLoS Negl Trop Dis. 2019. PMID: 31449535 Free PMC article.
Awareness and knowledge of Human Papillomavirus (HPV), HPV-related cancers, and HPV vaccines in an uninsured adult clinic population.
Radecki Breitkopf C, Finney Rutten LJ, Findley V, Jacobson DJ, Wilson PM, Albertie M, Jacobson RM, Colón-Otero G. Radecki Breitkopf C, et al. Cancer Med. 2016 Nov;5(11):3346-3352. doi: 10.1002/cam4.933. Epub 2016 Oct 17. Cancer Med. 2016. PMID: 27748078 Free PMC article.

See all "Cited by" articles

References

1. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–1056. - PubMed
1. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–F23. - PubMed
1. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–314. - PubMed
1. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–1927. - PubMed
1. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103(19):1444–1451. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

Intramural NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information

[1] de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–1056. - PubMed

[2] de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–1056. - PubMed

[3] Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–F23. - PubMed

[4] Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–F23. - PubMed

[5] Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–314. - PubMed

[6] Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–314. - PubMed

[7] Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–1927. - PubMed

[8] Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–1927. - PubMed

[9] Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103(19):1444–1451. - PMC - PubMed

[10] Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103(19):1444–1451. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents

Affiliations

The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical